MX2017016533A - Metodo para tratar glomeruloesclerosis focal y segmentaria primaria. - Google Patents

Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.

Info

Publication number
MX2017016533A
MX2017016533A MX2017016533A MX2017016533A MX2017016533A MX 2017016533 A MX2017016533 A MX 2017016533A MX 2017016533 A MX2017016533 A MX 2017016533A MX 2017016533 A MX2017016533 A MX 2017016533A MX 2017016533 A MX2017016533 A MX 2017016533A
Authority
MX
Mexico
Prior art keywords
focal segmental
segmental glomerulosclerosis
treating primary
primary focal
patient
Prior art date
Application number
MX2017016533A
Other languages
English (en)
Inventor
R Ledbetter Steven
Engstrand Sara
Finn Patrick
Lin Julie
John Pomponio Robert
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2017016533A publication Critical patent/MX2017016533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describe un método para tratar glomeruloesclerosis focal y segmentaria primaria en un paciente que tiene una variante APOL1, que comprende administrar intravenosamente un antagonista TGFß al paciente.
MX2017016533A 2015-06-19 2016-06-17 Metodo para tratar glomeruloesclerosis focal y segmentaria primaria. MX2017016533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182102P 2015-06-19 2015-06-19
PCT/US2016/037963 WO2016205581A1 (en) 2015-06-19 2016-06-17 Method of treating primary focal segmental glomerulosclerosis

Publications (1)

Publication Number Publication Date
MX2017016533A true MX2017016533A (es) 2018-05-28

Family

ID=57546326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016533A MX2017016533A (es) 2015-06-19 2016-06-17 Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.

Country Status (13)

Country Link
US (1) US20190062416A1 (es)
EP (1) EP3310438A4 (es)
JP (1) JP2018517721A (es)
KR (1) KR20180019125A (es)
CN (1) CN108290054A (es)
AU (1) AU2016280832A1 (es)
CA (1) CA2989629A1 (es)
IL (1) IL256321A (es)
MX (1) MX2017016533A (es)
RU (1) RU2018101865A (es)
TW (1) TW201718010A (es)
WO (1) WO2016205581A1 (es)
ZA (1) ZA201708305B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7247227B2 (ja) * 2018-05-22 2023-03-28 アイオニス・ファーマシューティカルズ・インコーポレイテッド Ａｐｏｌ１発現のモジュレーター
US11976067B2 (en) 2022-01-18 2024-05-07 Maze Therapeutics, Inc. APOL1 inhibitors and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550217A (en) * 2004-03-31 2009-11-27 Genentech Inc Humanized anti-TGF-beta antibodies
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US20120003644A1 (en) * 2010-06-07 2012-01-05 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining predisposition to develop kidney diseases
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions

Also Published As

Publication number Publication date
CA2989629A1 (en) 2016-12-22
AU2016280832A1 (en) 2018-01-18
WO2016205581A1 (en) 2016-12-22
KR20180019125A (ko) 2018-02-23
IL256321A (en) 2018-02-28
RU2018101865A (ru) 2019-07-22
ZA201708305B (en) 2018-11-28
US20190062416A1 (en) 2019-02-28
EP3310438A4 (en) 2018-11-21
JP2018517721A (ja) 2018-07-05
TW201718010A (zh) 2017-06-01
EP3310438A1 (en) 2018-04-25
CN108290054A (zh) 2018-07-17

Similar Documents

Publication Publication Date Title
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
MX2023008686A (es) Polinucleotidos moduladores.
GB2541571A (en) Pharmaceutical compositions
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MY187540A (en) Compounds active towards bromodomains
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
EA201692534A1 (ru) Способы лечения гипотонии
NZ722600A (en) Methods of treating mild brain injury
MX2017012553A (es) Compuestos espirociclicos.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12017500602A1 (en) Methods for treating ocular conditions
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии